Adjuvant therapy for cutaneous malignant melanoma

Journal of the American Academy of Dermatology

Volumn 36, Issue 5 I, 1997, Pages 747-764

  Demierre, M F ^a   Koh, H K ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; CYCLOPHOSPHAMIDE; DACARBAZINE; GAMMA INTERFERON; GANGLIOSIDE GM2; LEVAMISOLE; MEGESTROL ACETATE; MELANOMA VACCINE; PLACEBO; RETINOL; SEMUSTINE; TRANSFER FACTOR; TUMOR CELL VACCINE; VACCINIA ONCOLYSATE; VINCRISTINE;

BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG MEGADOSE; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; IMPOTENCE; INTRADERMAL DRUG ADMINISTRATION; INTRALESIONAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LYMPH NODE METASTASIS; MELANOMA; META ANALYSIS; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REGIONAL PERFUSION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030954514     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(97)80329-5     Document Type: Review

References (154)

1. Koh H.K. Sober A.J. Harmon D.C. Adjuvant therapy of cutaneous malignant melanoma: a critical review Med Pediatr Oncol 13 1985 244 260
2. Burk M.W. Morton D.L. Adjuvant cancer therapy: rationale for its use Surg Clin North Am 61 1981 1245 1247
3. Block J.B. Isacoff W.E. Adjuvant chemotherapy in cancer Semin Oncol 4 1977 109 115
4. Weiss R.B. DeVita V.T. Jr Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects Ann Intern Med 91 1979 251 260
5. Zubrod C.G. Historic milestones in curative chemotherapy Semin Oncol 6 1979 490 505
6. Bonadonna G. Valagussa P. Molitemi A. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node positive breast cancer: the results of 20 years of followup N Engl J Med 332 1995 901 906
7. DerSimonian R. Charette L.J. McPeek B. Reporting on methods in clinical trials N Engl J Med 306 1982 1332 1337
8. Glastein E. Makuch R.W. Illusion and reality: practical pitfalls in interpreting clinical trials J Clin Oncol 2 1984 488 497
9. Bigby M. Gadenne A. Understanding and evaluating clinical trials J Am Acad Dermatol 34 1996 555 590
10. American Joint Committee on Cancer 4th ed. Handbook for staging of cancer 1993 JB Lippincott Philadelphia 159
11. Day C.L. Jr. Mihm M.C. Jr. Lew R.A. Cutaneous malignant melanoma: prognostic guidelines for physicians and patients CA Cancer J Clin 32 1982 113 122
12. Balch C.M. Soong S.J. Murad T.M. A multifactorial analysis of melanoma. III. Prognostic factors in melanoma patients with lymph node metastases (stage II) Ann Surg 193 1981 377 388
13. Buzzell R.A. Zitelli J.A. Favorable prognosis factors in recurrent and metastatic melanoma J Am Acad Dermatol 34 1996 798 803
14. Cohen M.H. Ketcham A.S. Felix E.L. Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma Ann Surg 186 1977 635 642
15. Callery C. Cochran A.J. Roe D.J. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes Ann Surg 196 1982 69 75
16. Roses D.F. Harris M.N. Gumport S.L. Regional lymph node dissection for malignant melanoma of the extremities Surgery 89 1981 654 659
17. DeVita V.T. Jr Fisher R.I. Natural history of malignant melanoma as related to therapy Cancer Treat Rep 60 1976 153 157
18. Day C.L. Jr. Sober A.J. Lew R.A. Malignant melanoma patients with positive nodes and relatively good prognoses: microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes Cancer 47 1981 955 962
19. Weintraub M. How to critically assess clinical drug trials Drug Ther 12 1982 131 148
20. Sacks H. Chalmers T.C. Smith H. Jr. Randomized versus historical controls for clinical trials Am J Med 72 1982 233 240
21. Feinstein A.R. An additional basic science for clinical medicine: II. The limitations of randomized trials Ann Intern Med 99 1983 544 550
22. Feinstein A.R. An additional basic science for clinical medicine: II. The challenges of comparison and measurement Ann Intern Med 99 1983 705 712
23. Lacher M.J. Patients and physicians as obstacles to a randomized trial Semin Oncol 8 1981 424 429
24. Diamond G.A. Forrester I.S. Clinical trials and statistical verdicts: probable grounds for appeal Ann Intern Med 98 1983 385 394
25. Freiman J.A. Chalmers T.C. Smith H. Jr. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial: survey of 71 “negative” trials N Engl J Med 299 1978 690 694
26. Young M.J. Bresnitz E.A. Strom B.L. Sample size nomograms for interpreting negative clinical trials Ann Intern Med 99 1983 248 251
27. Aleong J. Barlett D.E. Improved graphs for calculating sample sizes when comparing two independent binomial distributions Biometrics 35 1979 875 881
28. Day C.L. Jr. Mihm M.C. Jr. Sober A.J. Predictors of late deaths among patients with clinical stage I melanoma who have not had bony or visceral metastases within the fast five years after diagnosis J Am Acad Dermatol 8 1983 864 868
29. Koh H.K. Sober A.J. Fitzpatrick T.B. Late recurrence (beyond ten years) of cutaneous malignant melanoma JAMA 251 1984 1859 1862
30. [letter] McIllmurray M.B. Reeves W.G. Langman M.J.S. Active immunotherapy in malignant melanoma Br Med J 1 1978 579
31. Lew R.A. Day C.L. Jr. Harrist T.J. Multivariate analysis: some guidelines for physicians JAMA 249 1983 641 643
32. Kirkwood J.M. Studies of interferons in the therapy of melanoma Semin Oncol 18 1991 83 90
33. Stewart W.E. II The interferon system 1981 Springer-Verlag New York
34. Nathan C.F. Horowitz C.R. de la Harpe J. Administration of recombinant interferon y to cancer patients enhances monocyte secretion of hydrogen peroxide Proc Natl Acad Sci U S A 82 1985 8686 8690
35. Herlyn M. Guerry D. Koprowski H. Recombinant γ-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells J Immunol 134 1985 4226 4230
36. Houghton A.N. Thomson T.M. Gross D. Surface antigens of melanoma and melanocytes: specificity of induction of la antigens by human γ-interferon J Exp Med 160 1984 255 269
37. Creagan E.T. Ahmann D.L. Long H.J. Phase II study of recombinant interferon-gamma in patients with disseminated malignant melanoma Cancer Treat Rep 71 1987 843 844
38. Ernstoff M.S. Trautman T. Davis C.A. A randomized phase I/II study of cutaneous versus intermittent intravenous interferon gamma in patients with metastatic melanoma J Clin Oncol 5 1987 1804 1810
39. Balch C.M. Houghton A.N. Peter L.J. Cutaneous melanoma De Vita V.T. Hellman S. Rosenberg S.A. Cancer: principles and practice of oncology 1993 JB Lippincott Philadelphia 1612 1661
40. Kirkwood J.M. Strawderman M.H. Emstoff M.S. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 1996 7 17
41. [abstract] Grob J.J. Dreno B. Delaunay M. Results of the French multicenter trial on adjuvant therapy with interferon alfa-2a in resected primary melanoma (>1.5 mm) Proc Am Soc Clin Oncol 15 1996 437
42. Creagan E.T. Dalton R.J. Ahmann D.L. Randomized, surgical adjuvant clinical trials of recombinant interferon alfa-2a in selected patients with malignant melanoma J Clin Oncol 13 1995 2776 2783
43. Meyskens F.L. Kopecky K.J. Taylor C.W. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group Study J Natl Cancer Inst 87 1995 1710 1712
44. [abstract] Cascinelli N. Evaluation of efficacy of adjuvant rIFNa-2A in melanoma patients with regional nodal metastases Proc Am Soc Clin Oncol 14 1995 410
45. Balch C.M. Buzaid A.C. Finally, a successful adjuvant therapy for high-risk melanoma J Clin Oncol 14 1996 1 3
46. Häffner A.C. Garbe C. Burg G. The prognosis of primary and metastasizing melanoma: an evaluation of the TNM classification in 2,495 patients Br J Cancer 66 1992 856 861
47. Cascinelli N. Bufalino R. Marolda R. Regional nonnodal metastases of cutaneous melanoma Eur J Surg Oncol 12 1986 175 180
48. Coit D. Sauven P. Brennan M. Prognosis of thick melanoma of the trunk and extremity Arch Surg 125 1990 322 326
49. Crowley N.J. Seigler H.F. The role of elective lymph node dissection in the management of patients with thick cutaneous melanoma Cancer 66 1990 2522 2527
50. Wong J.H. Cagle L.A. Morton D.L. Lymphatic drainage of skin to a sentinel lymph node in a feline model Ann Surg 214 1991 637 641
51. Morton D.L. Wen D.R. Wong J.H. Technical details of mtraoperative lymphatic mapping for early stage melanoma Arch Surg 127 1992 392 399
52. Morton D.L. Wen D.R. Cochran A.J. Management of early stage melanoma by intracperative lymphatic mapping and selective lymphadenectomy: an alternative to routine lymphadenectomy or “watch and wait” Surg Oncol Clin North Am 1 1992 247 259
53. Glass L.F. Fenske N.A. Messina J.L. The role of selective lymphadenectomy in the management of patients with malignant melanoma Dermatol Surg 21 1995 979 983
54. Godellas C.V. Berman C.G. Lyman G. The identification and mapping of melanoma regional nodal metastases: minimally invasive surgery for the diagnosis of nodal metastases Am Surg 61 1995 97 101
55. Reintgen D.S. Cruse C.W. Berman C. The orderly progression of melanoma nodal metastases Ann Surg 220 1994 759 767
56. Wang X. Heller R. Van Voorhis N. Detection of submicroscopic lymph node metastases with polymerase chain reaction Ann Surg 220 1994 768 774
57. Blessing C. Feine U. Geiger L. Positron emission tomography and ultrasonography Arch Dermatol 13 1995 1394 1398
58. Böni R. Whole-body positron emission tomography: an accurate staging modality for metastatic melanoma Arch Dennatol 132 1996 833 834
59. Cole B.F. Gelber R.D. Goldhirsch A. A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer: International Breast Cancer Study Group Stat Med 14 1995 1771 1784
60. Cole B.F. Gelber R.D. Kirkwood J.M. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study J Clin Oncol 14 1996 2666 2673
61. Battayani Z. Grob J.J. Xerri L. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma Arch Dermatol 131 1995 443 447
62. [abstract] Mellado B. Colomber D. Castel T. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction correlates with stage and prognosis in malignant melanoma Proc Am Soc Clin Oncol 15 1996 433
63. Arbiser J.L. Angiogenesis and the skin: a primer J Am Acad Dermatol 34 1996 486 497
64. Sumner W.C. Spontaneous regression of melanoma: report of a case Cancer 6 1953 1040 1043
65. Sumner W.C. Foraker A.G. Spontaneous regression of human melanoma: clinical and experimental studies Cancer 13 1960 79 81
66. Irie R.F. Irie K. Morton D.L. A membrane antigen common to human cancer and fetal brain tissue Cancer Res 36 1976 3510 3517
67. Tai T. Paulson J.C. Cahan L.D. Ganglioside GM2 as a human tumor antigen (OFA-I-1) Proc Natl Acad Sci U S A 80 1983 5392 5396
68. Cahan L.D. Irie R.F. Singh R. Identification of a human neuroectodennal tumor antigen (OFA-1-2) as ganglioside GD2 Proc Natl Acad Sci U S A 79 1982 762 933
69. Morton D.L. Malmgren R.A. Holmes E.C. Demonstration of antibodies against human malignant melanoma by immunofluorescence Surgery 64 1968 233 240
70. Berd D. Maguire H.C. Jr. McCue P. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunological results in 64 patients J Clin Oncol 8 1990 1858 1867
71. Morton D.L. Foshag L.J. Hoon D.S. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine Ann Sung 216 1992 463 482
72. Mitchell M.S. Harel W. Kan-Mitchell J. Active specific immunotherapy of melanoma with allogeneic cell lysates: rationale, results, and possible mechanisms of action Ann N Y Acad Sci 690 1993 153 166
73. Boon T. De Plaen E. Lurquin C. Identification of tumor rejection antigens recognized by T lymphocytes Cancer Surv 13 1992 23 27
74. Anichini A. Maccalli D. Mortarini R. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T-cell clones from melanoma patients J Exp Med 177 1993 989 998
75. Brichard V. van Pel A. Wolfel T. The tyrosine gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas J Exp Med 178 1993 489 495
76. Van der Bruggen P. Traversari C. Chomez P. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma Science 254 1991 1643 1645
77. Gaugler B. Van den Eynde B. Van der Bruggen P. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes J Exp Med 179 1994 921 930
78. Bakker A.B.H. Schreurs M.W.J. De Boer A.J. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes J Exp Med 179 1994 1005 1009
79. Kawakami Y. Eliyahu S. Delgado C.H. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor Proc Natl Acad Sci U S A 91 1994 3515 3519
80. Coulie P.G. Brichard V. Van Pel A. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas J Exp Med 180 1994 35 42
81. [abstract] Hersey P. Coates A. McCarthy W.H. Interim analysis of a randomized trial of immunotherapy with vaccinia melanoma cell lysates (VMCL) following surgical removal of high risk melanoma Proc Am Assoc Cancer Res 37 1996 489
82. Wallack M.K. Sivanandham M. Balch C.M. A phase III randomized, double-blind, multi-institutional trial of vaccinia melanoma oncolysate-active specific immuno therapy for patients with stage II melanoma Cancer 75 1995 34 42
83. Oratz R. Dugan M. Roses D.F. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine Cancer Res 51 1991 3643 3647
84. Livingston P.O. Wong G.Y.C. Adluri S. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside J Clin Oncol 12 1994 1036 1044
85. Morton D.L. Adjuvant immunotherapy of malignant melanoma: status of clinical trials at UCLA Int J Immunother 2 1986 31 36
86. Terry W.D. Hodes R.J. Rosenberg S.A. Treatment of stage I and II malignant melanoma with adjuvant immunotherapy or chemotherapy: preliminary analysis of a prospective randomized trial Terry W.D. Rosenberg S.A. Immunotherapy of human cancer 1982 Elsevier North Holland New York 252 257
87. Aranha G.V. McKhann C.F. Grage T.B. Adjuvant immunotherapy of malignant melanoma Cancer 43 1979 1297 1303
88. Hedley D.W. McElwain T.J. Currie G.A. Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIb malignant melanoma and may promote early recurrence Br J Cancer 37 1978 491 496
89. McIllmurray M.B. Embleton M.J. Reeves W.B. Controlled trial of active immunotherapy in management of stage lIB malignant melanoma BMJ 1 1977 540 542
90. Berd D. Mastangelo M.J. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide Cancer Invest 6 1988 337 349
91. Livingston P.O. Natoli E.J. Calves M.J. Vaccines containing purified GNU ganglioside elicit GM2 antibodies in melanoma patients Proc Natl Acad Sci U S A 84 1987 2911 2915
92. Miller K. Abeles G. Oratz R. Improved survival of patients with melanoma with an antibody response to im- munization to a polyvalent melanoma vaccine Cancer 75 1995 495 502
93. Hedley D.W. McElwain T.J. Currie G.A. Tumor regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy Eur J Cancer 13 1977 1169 1173
94. Mitchell M.S. Kan-Mitchell J. Kempf R.A. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant Cancer Res 48 1988 5883 5893
95. Bystryn J.C. Clinical activity of a polyvalent melanoma antigen vaccine Recent Results Cancer Res 139 1995 337 348
96. Nelson J. Cancer vaccines, disappointing in the past, show promise J Natl Cancer Inst 88 1996 486 488
97. Bystryn J.C. Oratz R. Roses D.F. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma Cancer 69 1992 1157 1164
98. [abstract] Berd D. Maguire H.C. Nathan F.N. Autologous, DNP-modified vaccine as post-surgical adjuvant treatment of Stages III and IV melanoma Proc Am Soc Clin Oncol 14 1996 554
99. Mande R. B.C.G. vaccination N Engl J Med 290 1974 1413 1419
100. Mande R. B.C.G. vaccination N Engl J Med 290 1974 1458 1459
101. Morton D.L. Eilber F.R. Malmgren R.A. Immunological factors which influence response to immunotherapy in malignant melanoma Surgery 68 1970 158 164
102. Tan J.K.L. Ho V.C. Pooled analysis of the efficacy of Bacille Calmette-Guérin (BCG) immunotherapy in malignant melanoma J Dermatol Surg Oncol 19 1993 985 990
103. Czarnetski B.M. Macher E. Suciu S. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomized multicenter study (EORTC protocol 18781) Eur J Cancer 29A 1993 1237 1242
104. Bröcker E.B. Suter L. Czametski B.M. BCG innnunotherapy in stage I melanoma patients: Does it influence prognosis determined by HLA-DR expression in highrisk primary tumors? Cancer Immunol Immunother 23 1986 155 157
105. Paterson A.H.G. Willans D.J. Jerry L.M. Adjuvant BCG immunotherapy for malignant melanoma Can Med Assoc J 131 1984 744 748
106. Fisher R.I. Terry W.D. Hodes R.J. Adjuvant immunotherapy or chemotherapy for malignant melanoma: preliminary report of the National Cancer Institute ran domized clinical trial Surg Clin North Am 61 1981 1267 1277
107. Veronesi U. Adamus J. Aubert C. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma N Engl J Med 307 1982 913 916
108. Pinsky C.M. Oettgen H.F. Surgical adjuvant for malignant melanoma Surg Clin North Am 61 1981 1259 1266
109. Karakousis C.P. Emrich L.J. Adjuvant treatment of malignant melanoma with DTIC + Estracyt or BCG J Surg Oncol 36 1987 235 238
110. Cascinelli N. Rümke P. MacKie R. The significance of conversion of skin reactivity in efficacy of bacillus Calmette-Guérin adjuvant immunotherapy of stage It malignant melanoma Cancer Immunol Immunother 28 1989 282 286
111. Scott M.T. Corynebacterium parvum as an immunotherapeutic anticancer agent Semin Oncol 1 1974 367 378
112. Scott M.T. Bomford R. Comparison of the potentiation of specific tumor immunity in mice by Corynebacterium parvum J Natl Cancer Inst 57 1976 555 559
113. Lipton A. Harvey H.A. Balch C.M. Corynebacterium parvum versus bacille-Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma J Clin Oncol 9 1991 1151 1156
114. [abstract] Balch C.M. Murray D.R. Presant C. A randomized prospective comparison of BCG versus C. parvum adjuvant immunotherapy in melanoma patients with resected metastatic lymph nodes Proc Am Soc Clin Oncol 3 1984 263
115. Lipton A. Harvey H.A. Lawrence B. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma Cancer 51 1983 57 60
116. Thatcher N. Mene A. Banerjee S.S. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma Br J Surg 73 1986 111 115
117. Balch C.M. Smalley R.V. Bartolucci A.A. A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (stage 1): prognostic factors analysis and preliminary results of immunotherapy Cancer 49 1982 1079 1084
118. Tripodi D. Parks L.C. Brugmans J. Drug induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer N Engl J Med 289 1975 354 367
119. Renoux G. Renoux M. Levamisole inhibits and cures a solid malignant tumor and its pulmonary metastases in mice Nature 240 1972 217 218
120. Quirt I.C. Shelley W.E. Pater J.L. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 9 1991 729 735
121. Spitler L.E. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma J Clin Oncol 9 1991 736 740
122. Lejeune F.J. Macher E. Kleeberg U. An assessment of DTIC versus levami sole or placebo in the treatment of high risk stage I patients after surgical removal of a pri mary melanoma of the skin: a phase II adjuvant study (EORTC protocol 18761) Eur J Cancer Clin Oncol 24 1988 581 890
123. Loutfi A. Shakr A. Jerry M. Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma Clin Invest Med 10 1987 325 328
124. LoBuglio A. Neidhart J.A. A review of transfer factor immunotherapy in cancer Cancer 34 1974 1563 1570
125. Miller L.L. Spitler L.E. Allen R.E. A randomized, double-blind, placebo controlled trial of transfer factor as adjuvant therapy for malignant melanoma Cancer 61 1988 1543 1549
126. Bukowski R.M. Deodhar S. Hewlett J.S. Randomized controlled trial of transfer factor in stage ll malignant melanoma Cancer 51 1983 269 272
127. Tranum B.L. Dixon D. Quagliana J. Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study Cancer Treat Rep 71 1987 643 644
128. Quirt I.C. DeBoer G. Kersey P.A. Randomized controlled trial of adjuvant chemo-immunotherapy with DTIC and BCG after complete excision of primary mel anoma with a poor prognosis or melanoma metastases Can Med Assoc J 128 1983 929 936
129. Hill G.J. II Moss S.E. Golomb F.M. DTIC and combination therapy for melanoma Cancer 47 1981 2556 2562
130. Karakousis C.P. Didolkar M.S. Lopez R. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma Cancer Treat Rep 63 1979 1739 1743
131. Castel T. Estape J. Viñolas N. Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy Dermatologica 183 1991 25 30
132. Wood W.C. Cosimi A.B. Carey R.W. Randomized trial of adjuvant therapy for “high risk” primary malignant melanoma Surgery 83 1978 677 681
133. Sterchi J.M. Wells H.B. Case L.D. A randomized trial of adjuvant chemotherapy and immunotherapy in stage I and II cutaneous melanoma: an interim report Cancer 55 1985 707 712
134. Retsas S. Quigley M. Pectasides D. Clinical and histological involvement of regional lymph nodes in malignant melanoma: adjuvant vindesine improves survival Cancer 73 1994 2119 2130
135. Meisenberg B.R. Ross M. Vredenburgh J.J. Randomized trial of high dose chemotherapy with autologous bone marrow support as adjuvant therapy for high risk, multi-node-positive malignant melanoma J Natl Cancer Inst 85 1993 1080 1085
136. Creech O. Krementz E.T. Ryan R.F. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit Ann Surg 148 1958 616 632
137. Ghussen F. Krüger I. Smalley R.V. Hyperthermic perfusion with chemotherapy for melanoma of the extremities World J Surg 13 1989 598 602
138. Hafström L. Rudenstram C. Blomquist E. Regional perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities J Clin Oncol 9 1991 2091 2094
139. Lejeune F.J. Phase III adjuvant studies in operable malignant melanoma Anticancer Res 7 1987 701 706
140. Lienard D. Ewalenko P. Delmotti J.J. High-dose recombinant tumour necrosis factor alpha in combination with interferon gamma and melphalan in isolated perfu sion of the limbs for melanoma and sarcoma J Clin Oncol 10 1992 52 60
141. a in combination with interferon-gamma and melphalan in isolation perfusion World J Surg 16 1992 234 240
142. Fraker D.L. Alexander H.R. The use of tumour necrosis factor (TNF) in isolated perfusion: results and side effects. The NO results. Melanoma Res 4 1994 27 29
143. Fraker D.L. Alexander R. Andrich M. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor ne crosis factor, interferon gamma: results of a tumor necrosis factor dose-escalation study J Clin Oncol 14 1996 479 489
144. Creagan E.T. Cupps R.E. Ivins J.C. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study Cancer 42 1978 2206 2210
145. Sause W.T. Cooper J.S. Rush S. Fraction size in external beam radiation therapy in the treatment of melanoma Int J Radiat Oncol Biol Phys 20 1991 429 432
146. Ang K.K. Byers R.M. Peters L.J. Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma: preliminary results Arch Otolaryngol Head Neck Surg 116 1990 169 172
147. Meyskens F.L. The endocrinology of melanoma Rev Endocrine-related Cancer 9 1981 5 13
148. Fisher R.I. Neifeld J.P. Lippman M.E. Estrogen receptors in human malignant melanoma Lancet 2 1976 337 338
149. Shaw H.M. McGovern V.J. Milton G.W. The female superiority in survival in clinical stage II cutaneous malignant melanoma Cancer 49 1982 1941 1944
150. Creagan E.T. Ingle J.N. Schutt A.J. A prospective randomized controlled trial of megestrol acetate among high risk patients with resected malignant melanoma Am J Clin Oncol 12 1989 152 155
151. Meyskens F.L. Liu P.Y. Tuthill R.J. Randomized trial of Vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a South-west Oncology Group Study J Clin Oncol 12 1994 2060 2065
152. Lotan R. Effects of Vitamin A and its analogs (retinoids) on normal and neoplastic cells Biochem Biophys Acta 605 1980 33 91
153. Felix E.L. Lloyd B. Cohen M.H. Inhibition of the growth and development of a transplantable murine melanoma by Vitamin A Science 189 1975 886 888
154. Lotan R. Ciotta G. Nork E. Characterization of the effects of different retinoids on the in vitro growth of two malignant murine melanomas J Natl Cancer List 60 1978 1035 1041